
Journal Menu
► ▼ Journal Menu-
- Current Oncology Home
- Aims & Scope
- Editorial Board
- Reviewer Board
- Topical Advisory Panel
- Instructions for Authors
- Special Issues
- Topics
- Sections & Collections
- Article Processing Charge
- Indexing & Archiving
- Editor’s Choice Articles
- Most Cited & Viewed
- Journal Statistics
- Journal History
- Journal Awards
- Society Collaborations
- Conferences
- Editorial Office
Journal Browser
► ▼ Journal Browser-
arrow_forward_ios
Forthcoming issue
arrow_forward_ios Current issue - Volumes not published by MDPI
Need Help?
Announcements
15 September 2023
Current Oncology | World Lymphoma Awareness Day in 2023—“We Can’t Wait”

World Lymphoma Awareness Day (WLAD) takes place annually on September 15th. It is organized by the Lymphoma Coalition and was established in 2004 with the purpose of promoting public understanding of the various subtypes of lymphoma. Its primary objectives include educating people about recognizing symptoms, encouraging early diagnosis, and emphasizing the importance of timely treatment.
For World Lymphoma Awareness Day 2023, Current Oncology (ISSN: 1718-7729) has gathered open access academic research on the topic of lymphoma. We hope to share new scientific knowledge in the field of lymphoma with the world on this special day.
1. “CD5-Negative, CD10-Negative Low-Grade B-Cell Lymphoproliferative Disorders of the Spleen”
by John J. Schmieg, Jeannie M. Muir, Nadine S. Aguilera and Aaron Auerbach
Curr. Oncol. 2021, 28(6), 5124–5147; https://doi.org/10.3390/curroncol28060430
Available online: https://www.mdpi.com/1718-7729/28/6/430
2. “How to Diagnose and Treat CD5-Positive Lymphomas Involving the Spleen”
by José Cabeçadas, Victor E. Nava, Joao L. Ascensao and Maria Gomes da Silva
Curr. Oncol. 2021, 28(6), 4611–4633; https://doi.org/10.3390/curroncol28060390
Available online: https://www.mdpi.com/1718-7729/28/6/390
3. “A Review on Splenic Diffuse Red Pulp Small B-Cell Lymphoma”
by Elif Yilmaz, Arashpreet Chhina, Victor E. Nava and Anita Aggarwal
Curr. Oncol. 2021, 28(6), 5148–5154; https://doi.org/10.3390/curroncol28060431
Available online: https://www.mdpi.com/1718-7729/28/6/431
4. “Low-Grade Primary Splenic CD10-Positive Small B-Cell Lymphoma/Follicular Lymphoma”
by Rami Abdulbaki, Parastou Tizro, Victor E. Nava, Maria Gomes da Silva and João L. Ascensão
Curr. Oncol. 2021, 28(6), 4821–4831; https://doi.org/10.3390/curroncol28060407
Available online: https://www.mdpi.com/1718-7729/28/6/407
5. “Comprehensive Laboratory Diagnostic Workup for Patients with Suspected Intraocular Lymphoma including Flow Cytometry, Molecular Genetics and Cytopathology”
by Evgenii Shumilov, Paolo Mazzeo, Martin S. Zinkernagel, Myriam Legros, Naomi Porret, Lorenz Romagna, Detlef Haase, Georg Lenz, Urban Novak, Yara Banz et al.
Curr. Oncol. 2022, 29(2), 766–776; https://doi.org/10.3390/curroncol29020065
Available online: https://www.mdpi.com/1718-7729/29/2/65
6. “Intravascular Large B-Cell Lymphoma: A Review with a Focus on the Prognostic Value of Skin Involvement”
by Thomas Breakell, Heidi Waibel, Stefan Schliep, Barbara Ferstl, Michael Erdmann, Carola Berking and Markus V. Heppt
Curr. Oncol. 2022, 29(5), 2909–2919; https://doi.org/10.3390/curroncol29050237
Available online: https://www.mdpi.com/1718-7729/29/5/237
7. “Management of Marginal Zone Lymphoma: A Canadian Perspective”
by Anthea Peters, Mary-Margaret Keating, Anna Nikonova, Sarah Doucette and Anca Prica
Curr. Oncol. 2023, 30(2), 1745–1759; https://doi.org/10.3390/curroncol30020135
Available online: https://www.mdpi.com/1718-7729/30/2/135
8. “Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton’s Tyrosine Kinase Inhibitor in Canada”
by Graeme Ball, Christopher Lemieux, David Cameron and Matthew D. Seftel
Curr. Oncol. 2022, 29(3), 2021–2045; https://doi.org/10.3390/curroncol29030164
Available online: https://www.mdpi.com/1718-7729/29/3/164
9. “Novel, First-in-Human, Oral PCLX-001 Treatment in a Patient with Relapsed Diffuse Large B-Cell Lymphoma”
by Randeep Sangha, Neal M. Davies, Afshin Namdar, Michael Chu, Jennifer Spratlin, Erwan Beauchamp, Luc G. Berthiaume and John R. Mackey
Curr. Oncol. 2022, 29(3), 1939–1946; https://doi.org/10.3390/curroncol29030158
Available online: https://www.mdpi.com/1718-7729/29/3/158
10. “Novel Mutations in a Lethal Case of Lymphomatous Adult T Cell Lymphoma with Cryptic Myocardial Involvement”
by Taraneh Hashemi Zonouz, Rami Abdulbaki, Bidhan C. Bandyopadhyay and Victor E. Nava
Curr. Oncol. 2021, 28(1), 818–824; https://doi.org/10.3390/curroncol28010079
Available online: https://www.mdpi.com/1718-7729/28/1/79
14 September 2023
Current Oncology | Official Social Media Accounts Go Live
We are pleased to announce the official social media of Current Oncology:
- Twitter: https://twitter.com/CurrentOncology
- Facebook: https://www.facebook.com/CurrentOncologyMDPI
- LinkedIn: https://www.linkedin.com/company/current-oncology-mdpi
You are more than welcome to connect with us!
6 September 2023
Recap of Awards Granted to Scholars in 2022

MDPI is committed to supporting the academic community, nurturing talent and advancing science. Awards are an important part of the research landscape and play a vital role in helping academics gain recognition, especially young researchers as they embark on new research avenues.
In 2022, our journals presented a total number of 394 Awards, including Travel Awards, Young Investigator Awards, Best PhD Thesis Awards, Best Paper Awards, and Outstanding Reviewer Awards, with several winners announced for some of the awards. The total prize sum amounted to just under 580,000 Swiss francs (CHF), or approximately 650,000 US dollars. Overall, more than 720 scholars were awarded.
The majority of the awards were dedicated to young researchers in relatively early stages of their careers. This encompassed 66 of the afore-mentioned Travel Awards, 60 Young Investigator Awards, supporting research projects and conference attendance, as well as 51 Best PhD Thesis Awards. Additionally, 113 Best Paper Awards were given by our journals. The selection committees were entrusted with identifying the most impactful and novel research and review articles published in their journal within a given year.
MDPI will continue its support and recognition for the academic community moving forward, sponsoring new awards across disciplines. To learn more about all the awardees and their research projects in your field of study, please visit the following pages:
To explore more MDPI awards, please click here.
5 September 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Neuro-Oncology”
As Current Oncology (ISSN: 1718-7729) is open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Neuro-Oncology” shown below:
1. “State of the Art in Combination Immuno/Radiotherapy for Brain Metastases: Systematic Review and Meta-Analysis”
by Masoumeh Najafi, Amin Jahanbakhshi, Marzieh Gomar, Cinzia Iotti, Lucia Giaccherini, Omid Rezaie, Francesco Cavallieri, Letizia Deantonio, Lilia Bardoscia, Andrea Botti et al.
Curr. Oncol. 2022, 29(5), 2995–3012; https://doi.org/10.3390/curroncol29050244
Available online: https://www.mdpi.com/1718-7729/29/5/244
2. “Delayed Effect of Dendritic Cells Vaccination on Survival in Glioblastoma: A Systematic Review and Meta-Analysis”
by Salvatore Cozzi, Masoumeh Najafi, Marzieh Gomar, Patrizia Ciammella, Cinzia Iotti, Corrado Iaccarino, Massimo Dominici, Giacomo Pavesi, Chiara Chiavelli, Ali Kazemian et al.
Curr. Oncol. 2022, 29(2), 881–891; https://doi.org/10.3390/curroncol29020075
Available online: https://www.mdpi.com/1718-7729/29/2/75
3. “Classification of Brain Tumor from Magnetic Resonance Imaging Using Vision Transformers Ensembling”
by Sudhakar Tummala, Seifedine Kadry, Syed Ahmad Chan Bukhari and Hafiz Tayyab Rauf
Curr. Oncol. 2022, 29(10), 7498–7511; https://doi.org/10.3390/curroncol29100590
Available online: https://www.mdpi.com/1718-7729/29/10/590
4. “Brain Metastases among Cancer Patients Diagnosed from 2010–2017 in Canada: Incidence Proportion at Diagnosis and Estimated Lifetime Incidence”
by Jiaqi L. Liu, Emily V. Walker, Yuba Raj Paudel, Faith G. Davis and Yan Yuan
Curr. Oncol. 2022, 29(3), 2091–2105; https://doi.org/10.3390/curroncol29030169
Available online: https://www.mdpi.com/1718-7729/29/3/169
5. “Treatment of Older Adult Patients with Glioblastoma: Moving towards the Inclusion of a Comprehensive Geriatric Assessment for Guiding Management”
by Manik Chahal, Brian Thiessen and Caroline Mariano
Curr. Oncol. 2022, 29(1), 360–376; https://doi.org/10.3390/curroncol29010032
Available online: https://www.mdpi.com/1718-7729/29/1/32
6. “Focused Delivery of Chemotherapy to Augment Surgical Management of Brain Tumors”
by Yusuf Mehkri, Samuel Woodford, Kevin Pierre, Abeer Dagra, Jairo Hernandez, Mohammad Reza Hosseini Siyanaki, Mohammed Azab and Brandon Lucke-Wold
Curr. Oncol. 2022, 29(11), 8846–8861; https://doi.org/10.3390/curroncol29110696
Available online: https://www.mdpi.com/1718-7729/29/11/696
7. “Somatostatin Receptor Theranostics for Refractory Meningiomas”
by Betty Salgues, Thomas Graillon, Tatiana Horowitz, Olivier Chinot, Laetitia Padovani, David Taïeb and Eric Guedj
Curr. Oncol. 2022, 29(8), 5550–5565; https://doi.org/10.3390/curroncol29080438
Available online: https://www.mdpi.com/1718-7729/29/8/438
8. “Newly Diagnosed Multifocal GBM: A Monocentric Experience and Literature Review”
by Valentina Baro, Giulia Cerretti, Michela Todoverto, Alessandro Della Puppa, Franco Chioffi, Francesco Volpin, Francesco Causin, Fabio Busato, Pasquale Fiduccia, Andrea Landi et al.
Curr. Oncol. 2022, 29(5), 3472–3488; https://doi.org/10.3390/curroncol29050280
Available online: https://www.mdpi.com/1718-7729/29/5/280
9. “Prospective Evaluation of Kidney Function in Long-Term Survivors of Pediatric CNS Tumors”
by Natalia Stepien, Viktoria Handler, Johannes Gojo, Amedeo A. Azizi, Lisa Mayr, Chryssa Grylli, Daniela Schwarz, Monika Chocholous, Irene Slavc, Michael Boehm et al.
Curr. Oncol. 2022, 29(8), 5306–5315; https://doi.org/10.3390/curroncol29080421
Available online: https://www.mdpi.com/1718-7729/29/8/421
10. “Laser Interstitial Thermal Therapy in Grade 2/3 IDH1/2 Mutant Gliomas: A Preliminary Report and Literature Review”
by Gabrielle W. Johnson, Rowland H. Han, Matthew D. Smyth, Eric C. Leuthardt and Albert H. Kim Curr. Oncol. 2022, 29(4), 2550–2563; https://doi.org/10.3390/curroncol29040209
Available online: https://www.mdpi.com/1718-7729/29/4/209
5 September 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Gynecologic Oncology”
As Current Oncology (ISSN: 1718-7729) is open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Gynecologic Oncology” shown below:
1. “Risk-Reducing Options for High-Grade Serous Gynecologic Malignancy in BRCA1/2”
by Lauren Clarfield, Laura Diamond and Michelle Jacobson
Curr. Oncol. 2022, 29(3), 2132–2140; https://doi.org/10.3390/curroncol29030172
Available online: https://www.mdpi.com/1718-7729/29/3/172
2. “Minimally Invasive Surgery for Cervical Cancer in Light of the LACC Trial: What Have We Learned?”
by Omar Touhami and Marie Plante
Curr. Oncol. 2022, 29(2), 1093–1106; https://doi.org/10.3390/curroncol29020093
Available online: https://www.mdpi.com/1718-7729/29/2/93
3. “Outcomes of Enhanced Recovery after Surgery (ERAS) in Gynecologic Oncology: A Review”
by Steven P. Bisch and Gregg Nelson
Curr. Oncol. 2022, 29(2), 631–640; https://doi.org/10.3390/curroncol29020056
Available online: https://www.mdpi.com/1718-7729/29/2/56
4. “The Path to Eliminating Cervical Cancer in Canada: Past, Present and Future Directions”
by Hannah Caird, Jonathan Simkin, Laurie Smith, Dirk Van Niekerk and Gina Ogilvie
Curr. Oncol. 2022, 29(2), 1117–1122; https://doi.org/10.3390/curroncol29020095
Available online: https://www.mdpi.com/1718-7729/29/2/95
5. “Advances in Radiation Oncology for the Treatment of Cervical Cancer”
by Mame Daro Faye and Joanne Alfieri
Curr. Oncol. 2022, 29(2), 928–944; https://doi.org/10.3390/curroncol29020079
Available online: https://www.mdpi.com/1718-7729/29/2/79
6. “Safety Profile of Niraparib as Maintenance Therapy for Ovarian Cancer: A Systematic Review and Meta-Analysis”
by Antonia Pagkali, Ioannis Mamais, Adamantios Michalinos and Aris P. Agouridis
Curr. Oncol. 2022, 29(1), 321–336; https://doi.org/10.3390/curroncol29010029
Available online: https://www.mdpi.com/1718-7729/29/1/29
7. “Cervical Cancer Prevention and High-Risk HPV Self-Sampling Awareness and Acceptability among Women Living with HIV: A Qualitative Investigation from the Patients’ and Providers’ Perspectives”
by Daisy Le, Annie Coriolan Ciceron, Min Jeong Jeon, Laura Isabel Gonzalez, Jeanne A. Jordan, Jose Bordon and Beverly Long
Curr. Oncol. 2022, 29(2), 516–533; https://doi.org/10.3390/curroncol29020047
Available online: https://www.mdpi.com/1718-7729/29/2/47
8. “Gynecologic Symptoms among Hormone Receptor-Positive Breast Cancer Patients on Oral Endocrine Therapy: A Cross-Sectional Study”
by Alexandra Moskalewicz, Amy Di Tomaso, Jacob J. Kachura, Samantha Scime, Rosane Nisenbaum, Ronita Lee, Rashida Haq, Christine Derzko and Christine Brezden-Masley
Curr. Oncol. 2022, 29(3), 1813–1827; https://doi.org/10.3390/curroncol29030149
Available online: https://www.mdpi.com/1718-7729/29/3/149
30 August 2023
MDPI Insights: The CEO's Letter #3 - Sustainability and Co-opetition

Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
Our Commitment to Sustainability
As a pioneer in academic open access publishing since 1996, MDPI has always been dedicated to facilitating scientific exchange across all disciplines. Our approach to open science is guided by principles such as Open Access (OA), Timeliness and Efficiency, Simplicity, High-Quality Service, Flexibility, and a commitment to Sustainability. This commitment involves preserving published papers for the long term and supporting the future of science through partnerships, sponsorships, and awards.
In this edition of the CEO Letter, I will delve into MDPI’s various sustainability initiatives. As a leader in OA publishing, we are able to provide the public with a significant amount of environment-related content at no cost.
MDPI and the Sustainable Development Goals (SDGs)
In 2020, the SDG Publishers Compact was launched to accelerate implementation of the SDGs by promoting content that informs, develops, and inspires action. MDPI joined this initiative in 2021 and subsequently launched the MDPI SDG Hub in 2022, offering free access to recent research within the scope of each of the 17 SDGs. We also support authors from underrepresented communities by waiving publication charges for selected SDG-related papers. Detailed sustainability practices and supported publications are available in the report under each Goal page.
“More than 80% of MDPI articles and reviews published in 2022 relate to the Sustainable Development Goals.” [source: InCites, Accessed on 21.08.2023]
As at August 2023, MDPI boasts 14 journals dedicated to sustainability-related topics. Our first journal in this area, Sustainability, has published over 29,000 articles on the SDGs, accumulating over 240,000 citations (source: InCites, as at 1 January 2023). These journals serve as vital platforms for researchers to share insights and address environmental challenges. In addition:
MDPI journals specializing in sustainability-related topics:
- 2009: Sustainability
- 2012: Resources
- 2013: Climate
- 2014: Environments
- 2016: Recycling
- 2019: Clean Technologies
- 2020: Sustainable Chemistry
- 2021: Wind, Biomass, Conservation, Pollutants, Solar
- 2022: Waste, Microplastics
Read more:
Impactful Research
Highly Cited Articles in Sustainability
In 2022, content published in Sustainability and indexed in Journal Citation Reports (JCR) received nearly 190,000 citations. This highlights the fact that Sustainability publishes highly cited research articles related to environmental sciences and SDG-related topics such as climate action.
We are pleased to share that Sustainability received a 2022 CiteScore of 5.8, marking a 16% increase from the 2021 metric. Specifically, the CiteScore positions Sustainability as follows: Q1 (27 out of 163) in the “Environmental Science (miscellaneous)” category, and Q1 (101 out of 779) in the “Geography Planning and Development” category. For additional journal statistics, please visit here.
“Sustainability received a 2022 CiteScore of 5.8”
While MDPI journals such as Climate and Atmosphere have a distinct focus on atmosphere pollution and its impact on climate processes, journals like Sustainability, Environments, Water, Remote Sensing, and IJERPH publish content related to climate change. These journals have published over 32,300 articles related to SDG 13: Climate Action.
Highly Cited Papers in Sustainability
Below are several highly cited papers published in Sustainability over the past three years. Citation metrics are current as at 15 August 2023.
1. “A Global Assessment: Can Renewable Energy Replace Fossil Fuels by 2050?”Authors: Jerry L. Holechek, Hatim M. E. Geli, Mohammed N. Sawalhah, and Raul Valdez
Sustainability 2022, 14(8), 4792; https://doi.org/10.3390/su14084792
Citations: Crossref (97), Scopus (91), Web of Science (82), Google Scholar (125)
This paper addresses one of the most significant challenges of climate change – achieving Net Zero Carbon by 2050. The meta-analysis suggests that while difficult, this transition is possible through the concerted application of pathways, lifestyle changes, and global cooperation.
2. “Anxiety and the Ecological Crisis: An Analysis of Eco-Anxiety and Climate Anxiety”Author: Panu Pihkala
Sustainability 2020, 12(19), 7836; https://doi.org/10.3390/su12197836
Citations: Crossref (144), Scopus (121), Web of Science (159), Google Scholar (382)
This paper has received substantial media attention, including coverage by The Guardian, BBC, Vice, and CNBC. An interview with Dr. Panu Pihkala, a leading interdisciplinary researcher on the topic, can be found on MDPI’s podcast: Insight Faster, Episode 1.
3. “Impact of Climate Change on Agriculture and Its Mitigation Strategies: A Review”Authors: Gurdeep Singh Malhi, Manpreet Kaur, and Prashant Kaushik
Sustainability 2021, 13(3), 1318; https://doi.org/10.3390/su13031318
Citations: Crossref (207), Scopus (221), Web of Science (186), Google Scholar (355)
This paper reviews literature on climate change, addressing its causes, future projections, impact on agriculture, including plant physiology, growth, productivity, pest infestation, and the economic implications of mitigation strategies.
4. “Impacts of Plastic Pollution on Ecosystem Services, Sustainable Development Goals, and Need to Focus on Circular Economy and Policy Interventions”Authors: Rakesh Kumar, Anurag Verma, Arkajyoti Shome, Rama Sinha, Srishti Sinha, Prakash Kumar Jha, Ritesh Kumar, Pawan Kumar, Shubham, Shreyas Das, Prabhakar Sharma, and P. V. Vara Prasad
Sustainability 2021, 13(17), 9963; https://doi.org/10.3390/su13179963
Citations: Crossref (134), Scopus (136), Web of Science (113), Google Scholar (184)
This review aims to assess the adverse effects of plastic pollution on ecosystems, link the management of plastic with the SDGs, and propose policy measures using transdisciplinary approaches. Empowering communities to reduce plastic use is crucial. Addressing global plastic pollution is a priority.
Sustainability is an international, cross-disciplinary, open access journal that explores environmental, cultural, economic, and social sustainability of human beings. It provides a forward-looking platform for research on sustainability and sustainable development, and is published semi-monthly online by MDPI. Sustainability is affiliated with The Canadian Urban Transit Research & Innovation Consortium (CUTRIC) and The International Council for Research and Innovation in Building and Construction (CIB).
Read more:
- Testimonials: See what our editors and authors say about Sustainability.
Inside MDPI
President of Ireland Authors Editorial in MDPI Journal Sustainability
It’s a very special occasion when the president of a country takes the initiative to write an editorial for a journal. Michael D. Higgins, President of the Republic of Ireland, has contributed his insights to a forthcoming Special Issue in Sustainability:
This Special Issue, focusing on “making sustainable development happen” at grassroots levels, allows for perspectives from, and on, the major world faiths, exploring how challenges have been conceptualised and addressed, in addition to case studies of faith-based sustainability initiatives in practice.
The experience of faith institutions and communities in translating theological and moral commitments to sustainable development into action is now a topic we must examine with urgency; one on which I am so glad this Special Issue focuses.
As President of Ireland, I very much support this Special Issue of Sustainability. It is my great hope that the contents of the papers contained herein will assist in making sustainable development happen at grassroots levels across the world so that we can cooperate together, people of faith and of none, to ensure a just, inclusive and sustainable future for all on our fragile planet.
Read the completed editorial here:
Special Issue “Faith and Sustainable Development: Exploring Practice, Progress and Challenges among Faith Communities and Institutions”: Foreword by the President of Ireland
Author: Michael D. Higgins
Sustainability 2023, 15(12), 9683; https://doi.org/10.3390/su15129683
Coming Together for Science
The World Sustainability Forum 2023
The World Sustainability Forum (WSF) is a biennial MDPI event focused on sustainability. WSF 2023 marks the tenth anniversary of the conference series, taking place on 14 September. For the first time, the event will be hosted as a 24-hour conference across three locations – Singapore, Basel in Switzerland, and Toronto in Canada – alongside virtual streaming.
This unique format allows us to span three time zones, providing live coverage of critical sustainability-related topics throughout the day:
- The Singapore Hub, chaired by Professor Horn Mun Cheah and Associate Professor Renee Tan, will explore “Sustainability for Social and Community Impact”.
- The Basel Hub, chaired by Prof. Dr. Anet Režek Jambrak and Dr. Lela Mélon, will delve into “Sustainability in the industry, and at university and corporate settings”.
- The Toronto Hub, led by Dr. Umberto Berardi, will discuss “The Sustainable Built Environment”.
MDPI Sustainability Foundation: Recognizing Excellence in Sustainability Research
The MDPI Sustainability Foundation supports researchers through two sustainability-focused awards:
- The World Sustainability Award, amounting to USD 100,000, is given to senior researchers.
- The Emerging Sustainability Leader Award, valued at USD 20,000, sponsored by the journal Sustainability, is presented to early-career researchers.
The winners of the Sustainability Foundation will be formally awarded during the WSF2023 on 14 September. Interviews with the award winners and finalists are available below.
2023 World Sustainability Award Winners
Interviews with 2023 Emerging Sustainability Leader Award Finalists
- Dr. Bahareh Kamranzad
- Dr. Youjin Kim
- Dr. Julia Lohmann
As a hybrid event, WSF23 provides scholars with the option to attend in person at one of the conference sites or, for a more sustainable approach, virtually. All sessions will be recorded and archived for future access. Registration is open until 3 September 2023, with in-person and virtual tickets available here.
Read more:
Closing Thoughts
“Co-opetition”: Collaboration Plus Healthy Competition – A Visit to Elsevier
I firmly believe in fostering collaboration and at the same time promoting healthy competition within the academic publishing industry. The market offers ample room for publishers and related companies to provide valuable services and products that enrich the academic community. While MDPI is recognized for its efficient and streamlined processes –thanks to our over 6,000 colleagues, in-house tools, and initiatives that support the author journey – our ethos has always involved learning from and collaborating with other organizations.
MDPI’s Interaction with Elsevier
In January 2023, I had a brief conversation with Judy Verses, President of Global Academic and Government Markets at Elsevier, following her participation in a panel discussion at the Academic Publishers Europe event in Berlin. One of the highlights for me was Judy’s insight into the impact of research, particularly her emphasis on the role of collaboration, including policy and showing the impact of research to influence on funding decisions.
“Such collaborations drive forward-looking strategies to elevate our support for the scholarly community”
Judy and I resumed our discussion in August, when I visited Elsevier's office to review current projects, such as our recent agreement with Science Direct and the continued indexing of MDPI journals in Scopus (indexing database owned by Elsevier). We also explored possible opportunities for the future, including a potential collaboration to expand MDPI’s Scilit data infrastructure. This endeavour aims to aggregate and provide access to scholarly metadata encompassing journal articles, conference papers, books, preprints, and more. While these discussions are ongoing, the underlying principle remains that such collaborations drive forward-looking strategies to elevate our services and support for the scholarly community.
It was great that Judy and I acknowledged the merits of 'co-opetition,' a concept based of the belief that fostering cooperation alongside healthy competition can lead to shared advancements for both individual companies and the industry at large.
‘Fully OA’ Organizations Dedicated to Open Access
MDPI proudly aligns with the ‘Fully OA’ group, a collaborative initiative comprising nine organizations dedicated to Open Access. Our monthly meetings, including an OASPA representative, serve as platforms to share non-confidential information, resources, and projects. These gatherings also facilitate discussions on topics relevant to fully OA organizations. Occasionally, joint actions spring from these interactions, such as collaborative blog posts on pertinent subjects and joint statements, such as a recent response to the House Appropriations Committee.
This display of cooperation among competing entities forms a strategic alliance focused on nurturing the best interests of the OA publishing model.
As I wrap up this third edition of the CEO Letter, I encourage you to seize opportunities for collaboration and contribute to advancing our shared academic culture. As the African proverb has it, “If you want to go fast, go alone; if you want to go far, go together.”
Chief Executive Officer
MDPI AG
22 August 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Genitourinary Oncology”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top highly cited papers in the Section “Genitourinary Oncology” shown below:
1. “Current Advances in Immune Checkpoint Inhibition and Clinical Genomics in Upper Tract Urothelial Carcinoma: State of the Art”
by Gianluigi Califano, Idir Ouzaid, Paul Laine-Caroff, Arthur Peyrottes, Claudia Collà Ruvolo, Benjamin Pradère, Vincent Elalouf, Vincent Misrai, Jean-François Hermieu, Shahrokh F. Shariat et al.
Curr. Oncol. 2022, 29(2), 687–697; https://doi.org/10.3390/curroncol29020060
Available online: https://www.mdpi.com/1718-7729/29/2/60
2. “Nondetectable Prostate Carcinoma (pT0) after Radical Prostatectomy: A Narrative Review”
by Nikolaos Kalampokis, Nikolaos Grivas, Markos Karavitakis, Ioannis Leotsakos, Ioannis Katafigiotis, Marcio Covas Moschovas, Henk van der Poel and the European Association of Urology (EAU) Young Academic Urologists (YAU) Robotic Urology Working Group
Curr. Oncol. 2022, 29(3), 1309–1315; https://doi.org/10.3390/curroncol29030111
Available online: https://www.mdpi.com/1718-7729/29/3/111
3. “Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study”
by Elodie Dang, Alexandre Vallée, Coralie Lepage-Seydoux, Karine Sejean, Brigitte Bonan, Christine Abraham, Philippe Beuzeboc and Raffaele Ratta
Curr. Oncol. 2022, 29(2), 945–955; https://doi.org/10.3390/curroncol29020080
Available online: https://www.mdpi.com/1718-7729/29/2/80
4. “Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies”
by Ioannis A. Voutsadakis
Curr. Oncol. 2022, 29(3), 1390–1407; https://doi.org/10.3390/curroncol29030117
Available online: https://www.mdpi.com/1718-7729/29/3/117
5. “Trop-2 in Upper Tract Urothelial Carcinoma”
by Eisuke Tomiyama, Kazutoshi Fujita, Kosuke Nakano, Ken Kuwahara, Takafumi Minami, Taigo Kato, Koji Hatano, Atsunari Kawashima, Motohide Uemura, Tetsuya Takao et al.
Curr. Oncol. 2022, 29(6), 3911–3921; https://doi.org/10.3390/curroncol29060312
Available online: https://www.mdpi.com/1718-7729/29/6/312
6. “Diagnostic and Therapeutic Challenges in a Patient with Synchronous Very High-Risk Prostate Adenocarcinoma and Anal Carcinoma”
by Jonathan Wallach, Irini Youssef, Andrea Leaf and David Schwartz
Curr. Oncol. 2022, 29(1), 377–382; https://doi.org/10.3390/curroncol29010033
Available online: https://www.mdpi.com/1718-7729/29/1/33
7. “Genomics and Immunomics in the Treatment of Urothelial Carcinoma”
by Veronica Mollica, Francesco Massari, Alessandro Rizzo, Roberto Ferrara, Arjun K. Menta and Jacob J. Adashek
Curr. Oncol. 2022, 29(5), 3499–3518; https://doi.org/10.3390/curroncol29050283
Available online: https://www.mdpi.com/1718-7729/29/5/283
8. “Next Wave of Targets in the Treatment of Advanced Renal Cell Carcinoma”
by Luisa M. Cardenas, Jasna E. Deluce, Shahrukh Khan, Omar Gulam, Saman Maleki Vareki, Ricardo Fernandes and Aly-Khan A. Lalani
Curr. Oncol. 2022, 29(8), 5426–5441; https://doi.org/10.3390/curroncol29080429
Available online: https://www.mdpi.com/1718-7729/29/8/429
9. “Clinical Lymph Node Involvement as a Predictor for Cancer-Specific Survival in Patients with Penile Squamous Cell Cancer”
by Makoto Kawase, Kimiaki Takagi, Kei Kawada, Takashi Ishida, Masayuki Tomioka, Torai Enomoto, Shota Fujimoto, Tomoki Taniguchi, Hiroki Ito, Koji Kameyama et al.
Curr. Oncol. 2022, 29(8), 5466–5474; https://doi.org/10.3390/curroncol29080432
Available online: https://www.mdpi.com/1718-7729/29/8/432
10. “The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature”
by Hana Studentova, Nikol Rusarova, Andrea Ondruskova, Anezka Zemankova, Vladimir Student Jr., Daniela Skanderova and Bohuslav Melichar
Curr. Oncol. 2022, 29(8), 5475–5488; https://doi.org/10.3390/curroncol29080433
Available online: https://www.mdpi.com/1718-7729/29/8/433
22 August 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Thoracic Oncology”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top highly cited papers in the Section “Thoracic Oncology” shown below:
1. “ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date”
by Sébastien Gendarme, Olivier Bylicki, Christos Chouaid and Florian Guisier
Curr. Oncol. 2022, 29(2), 641–658; https://doi.org/10.3390/curroncol29020057
Available online: https://www.mdpi.com/1718-7729/29/2/57
2. “Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology”
by Hamid Mithoowani and Michela Febbraro
Curr. Oncol. 2022, 29(3), 1828–1839; https://doi.org/10.3390/curroncol29030150
Available online: https://www.mdpi.com/1718-7729/29/3/150
3. “Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence”
by Ilaria Attili, Antonio Passaro, Pasquale Pisapia, Umberto Malapelle and Filippo de Marinis
Curr. Oncol. 2022, 29(1), 255–266; https://doi.org/10.3390/curroncol29010024
Available online: https://www.mdpi.com/1718-7729/29/1/24
4. “Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer”
by Diana N. Ionescu, Tracy L. Stockley, Shantanu Banerji, Christian Couture, Cheryl A. Mather, Zhaolin Xu, Normand Blais, Parneet K. Cheema, Quincy S.-C. Chu, Barbara Melosky et al.
Curr. Oncol. 2022, 29(7), 4981–4997; https://doi.org/10.3390/curroncol29070396
Available online: https://www.mdpi.com/1718-7729/29/7/396
5. “Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with EGFR Gene Mutation–Case Report and a Literature Review”
by Anna Rekowska, Piotr Rola, Magdalena Wójcik-Superczyńska, Izabela Chmielewska, Paweł Krawczyk and Janusz Milanowski
Curr. Oncol. 2022, 29(5), 3531–3539; https://doi.org/10.3390/curroncol29050285
Available online: https://www.mdpi.com/1718-7729/29/5/285
6. “Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer”
by Shelley Kuang, Andrea S. Fung, Kirstin A. Perdrizet, Kaitlin Chen, Janice J. N. Li, Lisa W. Le, Michael Cabanero, Ola Abu Al Karsaneh, Ming S. Tsao, Josh Morganstein et al.
Curr. Oncol. 2022, 29(7), 4428–4437; https://doi.org/10.3390/curroncol29070352
Available online: https://www.mdpi.com/1718-7729/29/7/352
7. “Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy”
by Balázs Jóri, Markus Falk, Iris Hövel, Peggy Weist, Markus Tiemann, Lukas C. Heukamp and Frank Griesinger
Curr. Oncol. 2022, 29(9), 6628–6634; https://doi.org/10.3390/curroncol29090520
Available online: https://www.mdpi.com/1718-7729/29/9/520
8. “HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature”
by Laurent Mathiot, Guillaume Herbreteau, Siméon Robin, Charlotte Fenat, Jaafar Bennouna, Christophe Blanquart, Marc Denis and Elvire Pons-Tostivint
Curr. Oncol. 2022, 29(5), 3748–3758; https://doi.org/10.3390/curroncol29050300
Available online: https://www.mdpi.com/1718-7729/29/5/300
18 August 2023
MDPI’s 2022 Young Investigator Awards in Medicine and Pharmacology—Winners Announced

MDPI’s Young Investigator Awards recognize promising young researchers, acknowledge their contributions, and enhance communication among scientists. We are proud to present the winners for the year 2022 in medicine and pharmacology. The winners were selected by the journals’ Award Evaluation Committee.
We would like to warmly congratulate the awarded young investigators for their outstanding contributions. MDPI will continue to provide support and recognition to the academic community.
- Yuyan Jiang, Stanford University, USA
- Billy Wai-Lung Ng, Chinese University of Hong Kong, China
- Ashleigh Poh, The Olivia Newton-John Cancer Research Institute, Australia
- Miranda Fidler-Benaoudia, University of Calgary, Canada
- Bishal Gyawali, Queen’s University, Canada
- Shahnawaz Anwer, Hong Kong Polytechnic University, Hong Kong
- Jan Bednarsch, Universitätsmedizin Berlin, Germany
- Anda Mihaela Naciu, Fondazione Policlinico Universitario Campus Bio-Medico, Italy
- Jerome Lechien, University of Mons, Belgium
- Daniele Bertoglio, University of Antwerp, Belgium
- Gregor Fuhrmann, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany
- Haley Adcox, Virginia Commonwealth University, USA
About MDPI Awards:
In order to support the academic community, especially young researchers, and enhance communication among scientists, MDPI journals regularly offer various awards to researchers in specific fields. These awards, serving as a source of inspiration and a form of recognition, help to promote the influence of talented individuals who have made outstanding achievements and are making significant contributions to the advancement of their fields.
For more MDPI awards, please click here.
18 August 2023
MDPI’s 2022 Travel Awards in Medicine and Pharmacology—Winners Announced

We are proud to recognize the winners of MDPI’s 2022 Travel Awards in medicine and pharmacology category for their outstanding presentations.
MDPI journals regularly offer Travel Awards to encourage talented junior scientists to present their research at academic conferences in specific fields, which helps to enhance their influence.
The winners mentioned below were carefully selected by the journal editors based on an outline of their research and the work to be presented at an academic conference.
We would like to congratulate the winners of the 2022 Travel Awards and wish them success with their future research endeavors. MDPI will continue to enhance communication among scientists.
- Filip Jansåker, Lund University, Lund, Sweden
- Vanessa Silva, University of Trás-os-Montes and Alto Douro, Portugal
- Diego de Miguel Perez, Icahn School of Medicine at Mount Sinai, USA
- Luigi Russo, Italian Institute of Technology (IIT), Italy
- Sneha Sethi, University of Adelaide, Australia
- Xiyin Wang, Indiana University School of Medicine, USA
- Sonia Nath, University of Adelaide, Australia
- Konstantina Kritikou, Carol Davila University of Medicine and Pharmacy, Romania
- Adrien Holzgreve, The University Hospital of Munich, Germany
- Antonella Padella, Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l., Italy
- Susanna Cooper, St. George’s University of London, UK
- Renée Tillie, Maastricht University Medical Center, the Netherlands
- Max Lennart Eckstein, University of Bayreuth, Germany
- Lorenzo Bertani, University of Pisa, Italy
- Yuxue Cao, University of Queensland, Australia
- Flávia Sousa, Italian Institute of Technology, Italy
About MDPI Awards:
In order to support the academic community, especially young researchers, and enhance communication among scientists, MDPI journals regularly offer various awards to researchers in specific fields. These awards, serving as a source of inspiration and form ot recognition, help to promote the influence of talented individuals who have made outstanding achievements and are making significant contributions to their fields.
See more MDPI awards, please click here.